EICHOR
● Recruiting
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Condition: Advanced Solid Tumor · Unresectable Solid Tumor · Metastatic Solid Tumor · Sponsor: Massachusetts General Hospital
About this study
This study is researching whether the combination of Afatinib and Pemigatinib is safe and effective in FGFR altered unresectable or metastatic advanced solid tumors. The study is also trying to discover the highest doses of the study drugs that can be administered without causing any intolerable side effects. This research study involves the study drugs Afatinib and Pemigatinib.
This description comes directly from the study's public registry record.
Talk to the study team
Haley Ellis, MD · 617-724-4000 · hellis@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06302621